UNSPSC 51202412: Omalizumab

This classification denotes a monoclonal antibody with the molecular formula C6450H9916N1714O2023S38, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2P471X1Z11, more generally known as omalizumab. European Medicines Agency schedules omalizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12543MIG. The term OMALIZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46.

Most nations, for tariff and trade purposes, schedule Omalizumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, OMALIZUMAB remains US FDA's Preferred Term for this commodity.. Omalizumab bears US NLM identifiers UMLS ID C0910794 and NCI Concept Code C29299.

UNSPSC 51202412 Omalizumab is a Commodity code that does not accurately reflect the pharmaceutical and medical supply procurements being solicited by state and local governments in the recent opportunities block. The source shows state and local buyers procuring naloxone, drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, medical and first aid supplies for emergency response, and direct-to-manufacturer prescription programs — none of which are omalizumab (a monoclonal antibody for asthma and allergic conditions). While the code nominally refers to a single pharmaceutical product, the recent solicitations show state and local governments buying across a much broader spectrum of pharmaceuticals, medical supplies, and pharmacy benefit management services through competitive bidding, cooperative purchasing vehicles, and market research RFIs.

The issuing bodies include state health departments (Texas HHS Commission), county health systems (Seminole County, Florida), cities and municipal fire departments (Tampa Fire Department), and multistate cooperative purchasing alliances (MMCAP administered by Minnesota Department of Administration). Recent opportunities span Florida, Texas, Minnesota, and Oregon; representative solicitations include Seminole County's 2026 IFB for naloxone and drug deactivation systems with a response deadline of July 26, 2026; the City of Tampa's 2026 ITB for medical and first aid supplies for fire rescue operations with an estimated contract value of $700,000.00 and a 5 percent bid discount for certified Small Local Business Enterprises; MMCAP's 2026 RFP for generic pharmaceuticals and OTC products due March 26, 2026, distributed through authorized drug wholesalers; and the Texas HHS Commission's 2026 RFI on direct-to-manufacturer prescription programs. The code shows little relevant activity tied to omalizumab specifically and appears misaligned with the actual scope of work being purchased.